Hormones and mood: a deep dive into perimenopause
NCT ID NCT00001231
First seen Jun 27, 2026 · Last updated Sep 02, 2026 · Updated 11 times
Summary
This study looked at how hormone changes during perimenopause (the time around menopause) might affect mood and behavior. Over 1,100 women participated, including those with depression symptoms and healthy volunteers. No treatments were given; instead, researchers used surveys and blood tests to track hormone levels and mood over time.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
1,158 people
The number who actually took part.
- Started
-
Mar 1989
- Lead sponsor
-
A government research agency
The lead sponsor is the US National Institutes of Health.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Both depressed and asymptomatic women who are in the perimenopause.
- Ages
-
40 to 65 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
* INCLUSION CRITERIA: * Perimenopausal Subjects: * History within the last one year of at least one month with perimenopause-related mood or behavioral disturbances of at least moderate severity - that is, disturbances that are distinct in appearance and associated with a notable degree of functional impairment; * Age 40-65; * History of the onset of menstrual irregularity during the past six months but not greater than one year of amenorrhea (i.e., not postmenopausal); * Biological evidence of a deterioration of normal ovarian activity, specifically, plasma FSH levels persistently elevated (\> 14IU/L) (as recommended by the Stages of Reproductive Aging Workshop criteria (106)) drawn at two week intervals over a period of eight weeks; * No prior estrogen replacement therapy for treatment of perimenopausal physical or emotional symptoms within the last six months; and * In good medical health; * Subjects must be competent to comprehend the purpose of the screening process and to provide written informed consent and be willing to participate in NIMH IRB approved research protocols. * A control group of age-matched perimenopausal women who meet patient selection criteria with the exception of the presence of mood or behavioral disorders will also be sought. * Premenopausal women will be women who meet the following inclusion criteria for the longitudinal study participants: * Regular menstrual cycle function (21-34 days); * Absence of current mood or behavioral disturbance as determined by a structured diagnostic interview; * Plasma gonadotropin levels in pre-perimenopausal range (\<14 IU/L); * In good medical health; and * Medication free. EXCLUSION CRITERIA: * Primary general medical illness (i.e., appears to be causing the mood disorder); * Current antidepressant therapy (since this is a screening protocol for subsequent treatment studies in which participants must be untreated). Antidepressants will not be withheld from participants who need or want them; * Current alcohol or substance abuse or dependence (excluding nicotine) of sufficient magnitude to require independent, concurrent treatment intervention (e.g., antabuse or opiate treatment, but not including self-help groups); * Pregnant or lactating women; * Subjects who are unable to provide informed consent. * NIMH employees, staff and their immediate family members will be excluded from the study per NIMH policy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Mood disorder are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can online group therapy match In-Person for treating anxiety and depression?
- France pilots collaborative mental health model in primary care
- Nurse Check-Ins after suicide attempt show promise in preventing repeat crisis
- Online group therapy helps workers with depression get back on the job
- New therapy aims to help teens battling addiction and anxiety
- Brain study seeks to unravel loneliness in mental illness